Edwards Lifesciences Q2: Buy The Dip Amid Guidance Cut
Summary
- Edwards Lifesciences cut TAVR guidance, stock price dropped by over 31%.
- Recent acquisitions and divestiture of the Critical Care business show strategic focus on the structural heart market.
- Analyst reiterates 'Strong Buy' rating with a fair value of $72 per share, confident in long-term growth potential.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of EW either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.